IL103560A - Metal chelate formulation of antibodies - Google Patents

Metal chelate formulation of antibodies

Info

Publication number
IL103560A
IL103560A IL103560A IL10356092A IL103560A IL 103560 A IL103560 A IL 103560A IL 103560 A IL103560 A IL 103560A IL 10356092 A IL10356092 A IL 10356092A IL 103560 A IL103560 A IL 103560A
Authority
IL
Israel
Prior art keywords
antibody
immunoglobulin
composition
copper ions
campath
Prior art date
Application number
IL103560A
Other languages
English (en)
Other versions
IL103560A0 (en
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10703637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL103560(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of IL103560A0 publication Critical patent/IL103560A0/xx
Publication of IL103560A publication Critical patent/IL103560A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
IL103560A 1991-10-28 1992-10-27 Metal chelate formulation of antibodies IL103560A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919122820A GB9122820D0 (en) 1991-10-28 1991-10-28 Stabilised antibodies

Publications (2)

Publication Number Publication Date
IL103560A0 IL103560A0 (en) 1993-03-15
IL103560A true IL103560A (en) 1998-02-08

Family

ID=10703637

Family Applications (1)

Application Number Title Priority Date Filing Date
IL103560A IL103560A (en) 1991-10-28 1992-10-27 Metal chelate formulation of antibodies

Country Status (17)

Country Link
US (2) US5654403A (da)
EP (1) EP0612251B1 (da)
JP (1) JP2881499B2 (da)
AT (1) ATE161191T1 (da)
AU (1) AU674290B2 (da)
CA (1) CA2121257C (da)
DE (1) DE69223641T2 (da)
DK (1) DK0612251T3 (da)
ES (1) ES2112338T3 (da)
GB (1) GB9122820D0 (da)
GR (1) GR3025931T3 (da)
HK (1) HK1004325A1 (da)
IL (1) IL103560A (da)
MY (1) MY110207A (da)
SG (1) SG47905A1 (da)
WO (1) WO1993008837A1 (da)
ZA (1) ZA928296B (da)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976832A (en) * 1995-03-06 1999-11-02 Tonen Corporation DNA encoding novel calcium-binding proteins
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
SI0907735T2 (sl) * 1996-05-24 2010-01-29 Biogen Idec Inc Modulatorji tkivne regeneracije
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
DK1068238T3 (da) 1998-04-02 2013-01-14 Xintela Ab Integrinheterodimer og subunit deraf
US20030055231A1 (en) * 1998-10-28 2003-03-20 Jian Ni 12 human secreted proteins
US7883704B2 (en) * 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
EP1174509A4 (en) * 1999-03-29 2003-10-22 Kansai Tech Licensing Org Co cytidine deaminase
EP2264166B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
SE9902056D0 (sv) * 1999-06-03 1999-06-03 Active Biotech Ab An integrin heterodimer and an alpha subunit thereof
US6808902B1 (en) * 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US20020035107A1 (en) * 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US20020141970A1 (en) * 2001-03-05 2002-10-03 Pettit Dean K. Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
PL366469A1 (en) * 2001-04-05 2005-02-07 Immuno-Biological Laboratories Co, Ltd. Anti-osteopontin antibody and use thereof
PT1475101E (pt) * 2002-02-14 2010-12-22 Chugai Pharmaceutical Co Ltd Fármacos em solução contendo anticorpos
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
JP5116971B2 (ja) 2002-10-15 2013-01-09 インターセル アーゲー Ｂ群連鎖球菌の接着因子をコードする核酸、ｂ群連鎖球菌の接着因子、およびその使用
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
EP1652925B1 (en) 2003-07-15 2010-12-08 Chugai Seiyaku Kabushiki Kaisha IgM PRODUCTION BY TRANSFORMED CELLS AND METHODS FOR QUANTIFYING SAID IgM PRODUCTION
CA2540848C (en) 2003-10-01 2012-12-11 Kyowa Kirin Co., Ltd. Method for stabilizing antibody and stabilized solution-type antibody preparation
US7803914B2 (en) 2003-10-09 2010-09-28 Chugai Seiyaku Kabushiki Kaisha Methods for stabilizing protein solutions
EP1688432B1 (en) * 2003-10-09 2011-08-03 Chugai Seiyaku Kabushiki Kaisha Igm high concentration stabilized solution
JPWO2005063291A1 (ja) * 2003-12-25 2007-07-19 麒麟麦酒株式会社 抗体を含有する安定な水性医薬製剤
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
AU2005229457B2 (en) 2004-03-30 2010-11-25 Glaxo Group Limited Immunoglobulins
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
ES2707284T3 (es) * 2005-03-08 2019-04-03 Pfizer Prod Inc Composiciones de anticuerpo anti-CTLA-4
AU2006247039B2 (en) * 2005-05-19 2011-03-03 Amgen Inc. Compositions and methods for increasing the stability of antibodies
SG162788A1 (en) 2005-06-14 2010-07-29 Amgen Inc Self-buffering protein formulations
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
US20110008282A1 (en) * 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
ES2374845T3 (es) * 2006-05-22 2012-02-22 Xbiotech, Inc Tratamiento de cáncer con anticuerpos anti-il-1.
JP5631591B2 (ja) * 2006-10-06 2014-11-26 アムジエン・インコーポレーテツド 安定な抗体製剤
ES2925992T3 (es) * 2006-10-20 2022-10-20 Amgen Inc Formulaciones estables de polipéptidos
US7776331B1 (en) 2007-01-16 2010-08-17 Abbott Laboratories Methods of treating plaque psoriasis
NZ580379A (en) 2007-03-29 2012-10-26 Abbott Lab Crystalline anti-human il-12 antibodies
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
TWI461210B (zh) * 2008-03-18 2014-11-21 Abbvie Inc 治療牛皮癬的方法
HUE029003T2 (en) * 2008-05-30 2017-01-30 Xbiotech Inc IL-1 alpha antibodies
AU2009291536B2 (en) * 2008-09-12 2012-08-16 Xbiotech Inc. Targeting pathogenic monocytes
AU2009319856A1 (en) * 2008-11-28 2010-06-03 Abbvie Inc. Stable antibody compositions and methods for stabilizing same
AR074777A1 (es) 2008-12-19 2011-02-09 Glaxo Group Ltd Proteinas de union a antigeno
GB0904355D0 (en) * 2009-03-13 2009-04-29 Imp Innovations Ltd Biological materials and uses thereof
CA2760185A1 (en) * 2009-05-04 2010-11-11 Abbott Biotechnology Ltd. Stable high protein concentration formulations of human anti-tnf-alpha antibodies
MX2012003138A (es) * 2009-09-14 2012-07-04 Abbott Lab Y Abbott Gmbh & Co Kg Metodos para tratar la psoriasis.
WO2011038069A1 (en) * 2009-09-24 2011-03-31 Xbiotech, Inc. Methods, compositions, and kits for reducing anti-antibody responses
WO2011049082A1 (ja) * 2009-10-21 2011-04-28 国立大学法人広島大学 インテグリンα8β1特異的モノクローナル抗体
KR20130028055A (ko) 2010-01-28 2013-03-18 글락소 그룹 리미티드 Ｃｄ １２７ 결합 단백질
KR20120133382A (ko) 2010-02-09 2012-12-10 글락소 그룹 리미티드 대사 장애의 치료
KR20190047135A (ko) 2010-03-01 2019-05-07 바이엘 헬스케어 엘엘씨 조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 최적화된 모노클로날 항체
UA108227C2 (xx) 2010-03-03 2015-04-10 Антигензв'язуючий білок
UY33421A (es) 2010-06-03 2011-12-30 Glaxo Wellcome House Proteinas de union al antígeno humanizados
DK2582391T3 (da) 2010-06-18 2019-01-21 Xbiotech Inc Arthritis-behandling
WO2012027324A2 (en) 2010-08-23 2012-03-01 Xbiotech, Inc. Treatment for neoplastic diseases
EP2444101A1 (en) 2010-10-21 2012-04-25 Universitätsklinikum Freiburg Selective targeting of the CD40L/Mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis
ES2601202T3 (es) 2010-11-11 2017-02-14 Abbvie Biotechnology Ltd Formulaciones liquidas de anticuerpos anti-TNT-alfa de alta concentración
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
AU2012312225B2 (en) 2011-09-23 2017-10-05 Xbiotech Inc. Cachexia treatment
US9895437B2 (en) 2012-04-18 2018-02-20 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
KR20150043523A (ko) 2012-09-02 2015-04-22 애브비 인코포레이티드 단백질 불균일성의 제어 방법
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
WO2014143205A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US10081673B2 (en) * 2013-03-14 2018-09-25 Ffe Therapeutics Llc Compositions and methods for treating angiogenesis-related disorders
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
EP4470648A3 (en) 2015-08-13 2025-03-05 Amgen Inc. Charged depth filtration of antigen-binding proteins
WO2017049529A1 (en) 2015-09-24 2017-03-30 Innolife Co., Ltd. A pharmaceutical composition comprising a copper chelating tetramine and the use thereof
CA3053231A1 (en) 2017-02-16 2018-08-23 Xbiotech Inc. Treatment of hidradenitis suppurativa
CN110408600A (zh) * 2018-12-10 2019-11-05 浙江工商大学 一株分泌抗重金属铜离子单克隆抗体的杂交瘤细胞株及其应用
CA3095676A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095740A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin alpha (il-1a)
CA3095675A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095679A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleuken 1 alpha (il-1a)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2149304A (en) * 1936-04-20 1939-03-07 Sharp & Dohme Inc Lyophilic biologically active substances
JPS56145222A (en) * 1980-04-28 1981-11-11 Toshiyuki Hamaoka Improved antibody and its preparation
CA1308023C (en) * 1988-07-29 1992-09-29 William Austin James Mcauley Immunoglobulin extraction utilizing properties of colloidal solutions
US4933435A (en) * 1989-04-05 1990-06-12 Bioprobe International Antibody purification process
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
JPH0565233A (ja) * 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
US5367060A (en) * 1991-05-24 1994-11-22 Genentech, Inc. Structure, production and use of heregulin

Also Published As

Publication number Publication date
DK0612251T3 (da) 1998-04-27
AU674290B2 (en) 1996-12-19
US5792838A (en) 1998-08-11
AU2872992A (en) 1993-06-07
JPH07502497A (ja) 1995-03-16
HK1004325A1 (en) 1998-11-20
MY110207A (en) 1998-02-28
EP0612251B1 (en) 1997-12-17
ZA928296B (en) 1994-04-28
GB9122820D0 (en) 1991-12-11
JP2881499B2 (ja) 1999-04-12
CA2121257A1 (en) 1993-05-13
IL103560A0 (en) 1993-03-15
ATE161191T1 (de) 1998-01-15
US5654403A (en) 1997-08-05
SG47905A1 (en) 1998-04-17
DE69223641T2 (de) 1998-04-09
WO1993008837A1 (en) 1993-05-13
DE69223641D1 (de) 1998-01-29
GR3025931T3 (en) 1998-04-30
ES2112338T3 (es) 1998-04-01
CA2121257C (en) 1999-07-13
EP0612251A1 (en) 1994-08-31

Similar Documents

Publication Publication Date Title
US5654403A (en) Immunoglobulins stabilized with a chelator of copper ions
HK1004325B (en) Stabilised antibodies
US20230060847A1 (en) Anti-bcma heavy chain-only antibodies
US10266593B2 (en) Human CD3 binding antibody
AU2008275278B2 (en) Antibody formulations
US11421030B2 (en) BTLA antibodies
EP0842948B1 (en) ANTIFas LIGAND ANTIBODIES AND ASSAY METHOD BY USING THE SAME
JP2020524506A (ja) 抗ｂｃｍａ重鎖のみ抗体
KR20230008775A (ko) Cd3 및 cd20에 대한 이중특이적 항체
MX2014015262A (es) Formulacion de anticuerpos.
BRPI0413489B1 (pt) molécula de anticorpo anti-cd20 fusionada a il-2 e composição farmacêutica compreendendo a mesma
US20260042850A1 (en) Anti c-met antibodies
KR20010043470A (ko) Ｃｄ23에 대한 항체, 이의 유도체 및 이들의 치료적 용도
EP3714901A1 (en) Lag-3 antibody pharmaceutical composition and use thereof
US20220281965A1 (en) Antibodies directed against gdf-15
JP2012517806A (ja) ヒト化抗ｃｄ２０抗体および使用方法
CN112543647A (zh) 一种tim3抗体药物组合物及其用途
US20250177519A1 (en) Use of isatuximab in combination with other agents for the treatment of multiple myeloma
HK40089030A (zh) 针对cd3和cd20的双特异性抗体
HK1207652B (en) Antibody formulations
HK1141979B (en) Anti-cd20 antibody formulations

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired